News

There will likely be a national shortage of medical devices—including CV tools like stents, shunts and catheters—in the near future, according to the FDA.

Facebook introduced a new tool this week that provides the platform’s users with personalized healthcare recommendations, CNN reports.

Cardiac care is suffering at hospitals that experience data breaches, PBS reported Oct. 24, with one study finding that heart attack rates soar in the weeks and months after a center’s cybersecurity is compromised.

Cardiology is in the midst of a major transition from one of its best-loved tools—the stethoscope—to more high-tech handheld solutions, according to the AP. But does that mean the original device is becoming obsolete?

The largest study of its kind has found that taking blood pressure medication at bedtime—as opposed to first thing in the morning—lowers heart patients’ risk of death and CV-related illness in the long run.

Weight gain during early training causes cardiovascular problems for collegiate football players.

Post-traumatic stress disorder (PTSD) may increase the risk of transient ischemic attack and stroke in middle age.

Philips is the first big name to sign on as a sponsor of Cardio Ex, a heart-themed medical video game targeted at interventional cardiologists, Medical Design & Outsourcing reported Oct. 21.

A smartphone app introduced at the 45th Argentine Congress of Cardiology (SAC 2019) this week in Buenos Aires improved heart patients’ adherence to their drug regimen after a CV event.

Pregnant women may soon be able to assess their own risk of preeclampsia, according to work published in the Journal of Engineering and Science in Medical Diagnostics and Therapy

A novel machine learning algorithm improved patient selection for CRT in a study of nearly 1,000 heart failure patients, representing an opportunity to optimize care and spare certain individuals from a pricey procedure that might not benefit them.

Pharmaceutical company AstraZeneca announced Oct. 21 that its drug Farxiga—or dapagliflozin—was approved by the FDA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.